References
1. Volpicelli JR, Alterman AI, Hayashida M. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992. 49876–880.
2. Volpicelli JR. Alcohol abuse and alcoholism: an overview. J Clin Psychiatry 2001. 62Suppl 20. 4–10.
3. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004. 9921–24.
4. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA 1986. 2561449–1455.
5. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: Van evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003. 13469–475.
6. Durbin P, Hulot T, Chabac S. In : Soyka M, ed. Pharmacodynamics and pharmacokinetics of acamprosate : An overview. Acamprosate in Relapse Prevention of Alcoholism 1995. Berlin: Springer-Verlag; 47–64.
7. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 1996. 53673–680.
8. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol: Alcohol and Alcoholism. Alcohol Alcohol 1995. 30239–247.
9. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 1997. 17173–75.
10. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom multicentre acamprosate study (UKMAS): a 6 month prospective study of acamprosate vs placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000. 35176–187.
11. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Korean Acamprosate Clinical Trial Investigators. Acamprosate in Korean alcohol dependent patients: a multi-center, randomized, double-blind, placebo-ontrolled study. Alcohol. Alcohol Alcohol 2003. 38135–134.
12. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone. J Clin Psychiatry 1984. 4515–19.
13. Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry 1995. 56Suppl 7. 24–29.
14. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Veterans Affairs Naltrexone Cooperative Study 425 Group. naltrexone in the treatment of alcohol dependence[see comment]. N Engl J Med 2001. 3451734–1739.
Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial.
15. Croop RS, Labriola DF, Wroblewski JM, Nibbelink DW. A multicenter safety study of naltrexone as adjunctive pharmacotherapy for individuals with alcoholism. Presented at annual meeting of the American Psychiatric association 1995. 20–25.
16. Verebey K, Volavska J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effect after acute and chronic dosing. Clinical Pharmacology and Therapeutics 1976. 20315–328.
17. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. Journal of Clinical Psychopharmacology 2001. 21632–634.
18. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000. 284963–971.
19. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003. 3611677–1685.
20. Johnson BA, Swift RM, Ait DN, DiClemente CC, Javors MA, Malcolm RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res 2004. 28295–301.
21. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997. 54700–705.
22. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000. 241041–1049.
23. Naranjo CA, Bremner KE, Lanctot KL. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 1995. 9087–99.
24. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner R, Brown J, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994. 51720–731.
25. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994. 165515–523.
26. Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M, et al. A double-lind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res 2004. 28736–745.
27. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000. 26441–449.